Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

10x Genomics (TXG) EBITDA Margin (2018 - 2025)

10x Genomics (TXG) has disclosed EBITDA Margin for 8 consecutive years, with 11.77% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 1843.0% to 11.77% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 9.49% through Dec 2025, up 2237.0% year-over-year, with the annual reading at 9.49% for FY2025, 2237.0% up from the prior year.
  • EBITDA Margin hit 11.77% in Q4 2025 for 10x Genomics, up from 21.64% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 17.42% in Q2 2025 to a low of 61.7% in Q3 2023.
  • Historically, EBITDA Margin has averaged 26.36% across 5 years, with a median of 27.31% in 2024.
  • Biggest five-year swings in EBITDA Margin: skyrocketed 35735bps in 2021 and later plummeted -4554bps in 2022.
  • Year by year, EBITDA Margin stood at 12.97% in 2021, then fell by -14bps to 14.78% in 2022, then crashed by -103bps to 30.0% in 2023, then decreased by -1bps to 30.2% in 2024, then surged by 61bps to 11.77% in 2025.
  • Business Quant data shows EBITDA Margin for TXG at 11.77% in Q4 2025, 21.64% in Q3 2025, and 17.42% in Q2 2025.